Business Context and Reporting Period
Company: Xtant Medical Holdings, Inc. (XTNT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Xtant is a global medical technology company focused on orthobiologics and spinal implant fixation systems. The company operates in one reportable segment, serving orthopedic and neurological surgeons primarily in the United States (91% of revenue) and internationally.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $133,927 | $117,267 |
| Product Revenue | $115,204 | $115,765 |
| License Revenue | $18,723 | $1,502 |
| Gross Profit | $84,273 | $68,216 |
| Gross Margin | 62.9% | 58.2% |
| Net Income (Loss) | $4,973 | $(16,449) |
| Operating Cash Flow | $12,546 | $(11,896) |
| Cash and Cash Equivalents (Dec 31, 2025) | $17,328 | $6,221 |
| Total Debt Outstanding (Dec 31, 2025) | $24,857 | $34,120 |
Note: Total Debt includes $14.0 million in term loan principal and $10.9 million in revolving credit facility outstanding as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14% to $133.9 million, driven primarily by a surge in license revenue ($18.7 million in 2025 vs. $1.5 million in 2024) and increased orthobiologics volume. This was partially offset by a decline in hardware revenue.
- Profitability Turnaround: The company reported a net income of $5.0 million in 2025, reversing a net loss of $16.4 million in 2024. This was aided by a $3.3 million gain on divestiture and improved gross margins.
- Divestitures: On December 1, 2025, Xtant sold its Coflex/CoFix assets and international hardware business (Paradigm Spine GmbH) to Companion Spine for an aggregate purchase price of $21.4 million. This transaction generated a $3.3 million gain and provided significant cash proceeds.
- Debt Reduction: Proceeds from the divestitures were used to repay $8.0 million of term debt in 2025, reducing total principal outstanding.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Non-Recurring Revenue: Management explicitly states that the $18.7 million in license revenue recognized in 2025 is unlikely to repeat in 2026. This is due to CMS reimbursement changes effective January 1, 2026, affecting the SimpliMax and SimpliGraft products.
- Revenue Impact: The loss of the divested Coflex/CoFix and international hardware business (which generated $20.3 million in 2025 revenue) will adversely affect 2026 revenues.
- Liquidity: Management believes cash on hand ($17.3 million), proceeds from divestitures received in early 2026 ($10.7 million), and operating cash flows will be sufficient to meet requirements through March 2027.
Material Risks and Contingencies
- Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to the evaluation of inventory net realizable value. This resulted in an out-of-period adjustment in Q4 2025.
- Debt Covenants: The company had difficulty complying with minimum net revenue covenants under its Credit Agreements. An amendment executed in March 2026 waived the Q4 2025 requirement and revised the covenant to align solely with orthobiologics revenue.
- Regulatory Changes: New CMS reimbursement rules for skin substitutes (SimpliMax/SimpliGraft) implemented in 2026 are expected to reduce future license and product revenue.
- Inventory Valuation: The company recorded a $1.3 million charge for excess and obsolete inventory related to the Cortera Fixation System launch in Q4 2025.
Key Facts for Investor Verification
- Sustainability of 2025 Profitability: Verify the extent to which 2025 net income was driven by non-recurring license revenue ($18.7M) and the one-time gain on divestiture ($3.3M), both of which are expected to be absent or reduced in 2026.
- 2026 Revenue Guidance: Confirm management's specific revenue guidance for 2026 given the explicit warnings about the loss of $20.3M in divested hardware revenue and the $18.7M in license revenue.
- Debt Covenant Compliance: Monitor the company's ability to meet the revised minimum net revenue covenants focused on orthobiologics products, as failure could trigger default.
- Remediation of Internal Controls: Track the progress of remediation efforts for the material weakness in inventory valuation controls to ensure future financial reporting reliability.
- Cash Burn Rate: Assess whether operating cash flows from the remaining core business (orthobiologics and domestic hardware) are sufficient to cover operating expenses and debt service without the divested revenue streams.